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Abstract 
Background: Interferons (IFNs) have potent anti-proliferative, pro-apoptotic, and immunomodulatory activities 
against cancer. However, the clinical utility of IFNs is limited by toxicity and pharmacokinetics making it difficult to 
achieve sustained therapeutic levels especially in solid tumors.
Methods: Signal Transducer and Activator of Transcription 1 (STAT1) or a modified STAT1 (designated STAT1-CC) 
that is hyper-responsive to IFN were overexpressed in lung cancer SPC-A-1 and H1299 cells using lentiviral vectors. 
Transduction efficiency was monitored using enhanced green fluorescent protein (EGFP) expression. After transduc-
tion, cells were treated with interferon-gamma (IFN-γ) or interferon-beta (IFN-β) and monitored for cell proliferation, 
migration, and invasiveness using Cell Counting Kit-8 and transwell chamber assays and for apoptosis using Annexin 
V detection by flow cytometry. In addition, levels of STAT1, STAT1 Tyr-701 phosphorylation (pSTAT1), fibronectin, and 
β-catenin were determined using western blotting. In the case of IFN-γ stimulation, levels of S100A4, proliferating cell 
nuclear antigen (PCNA), and c-fos expression were also determined.
Results: We found that expression of STAT1 or STAT1-CC enhanced the effect of IFN-γ and, IFN-β on inhibition of 
human lung cancer cell proliferation, migration and invasiveness. Moreover, STAT1 and STAT1-CC expression caused 
increases in pSTAT1 and decreases in fibronectin and β-catenin levels. STAT1-CC showed increased effects compared 
to STAT1 on IFN-γ induced pSTAT1 and down-regulation of S100A4, PCNA, and c-fos levels.
Conclusion: The results show that STAT1-CC exhibited more strength in improving the antitumor response of IFNs in 
lung cancer cells. Results from this study suggest that combined treatment of IFNs and STAT1-CC might be a feasible 
approach for the clinical management of lung cancer in the future.
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Background
Lung cancer is a highly malignant disease with a dismal 
prognosis. For example, 80–85 % of lung cancer cases are 
categorized as non-small cell lung cancers [1], and the 
5-year overall survival rate of non-small cell lung cancer 
cases remains at less than 10 % despite improvements in 
surgery, radiotherapy, and chemotherapy [2]. Thus, novel 
treatment strategies are needed to improve the outcomes 
of lung cancer patients.
The use of interferons (IFNs) could be a potential strat-
egy in the treatment of lung cancer [3]. IFNs have been 
shown to have anti-proliferative, anti-angiogenic, pro-
apoptotic, and immunoregulatory effects [3]. Type I 
IFNs (the IFN-α family and IFN-β) have been used with 
some success for the treatment of several types of cancer, 
including hematological malignancies and solid tumors 
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[4]. Type II, IFN-γ, also has antitumor activities in vari-
ous types of cancer [5, 6]. Unfortunately, although IFNs 
have impressive potential activities against cancer, the 
clinical utility of IFNs in the treatment of solid tumors 
has been limited [3, 5]. The half-life of the  intra-tumor 
concentration  was short, thus requiring high doses of 
IFNs for a therapeutic effect that would result in toxic 
side effects [3, 5].
The IFN/STAT1 pathway is a typical signaling pathway 
that mediates crosstalk between tumor cells and compo-
nents of the host microenvironment [7, 8]. IFN activities 
rely on signaling through three types of IFN receptors (for 
type I, II, and III IFNs) and the Janus activated kinase-
signal transducer and activator of transcription (JAK-
STAT) pathway that includes receptor-associated JAKs 
and STATs as well as downstream modulators, transcrip-
tion factors, enhancers, and coactivators. STAT1 is a cen-
tral mediator for IFN-related intracellular signaling and 
is considered a tumor suppressor protein related to the 
IFNs [9]. The role of STAT1 in the IFN-signaling path-
way in the context of its antiviral actions has been exten-
sively studied [10]. Previous studies have shown that 
modified STAT1 (STAT1-CC, the SH2 domain of STAT1 
Ala-656 and Asn-658 site with double-cysteine alterna-
tive) broadly improves IFN signal transduction in human 
cells [11]. Compared to wild-type STAT1, STAT1-CC 
increases the capacity of STAT1 Tyr-701 phosphoryla-
tion (pSTAT1), nuclear translocation, DNA binding, 
recruitment of p300/CBP coactivator, and thus IFN effi-
cacy. Encephalomyocarditis viral replication is inhibited 
in STAT1-CC-expressing cells, a finding which further 
extends the benefits of STAT1-CC [11]. Overexpression 
of STAT1-CC in a IFN-resistant cell line results in IFN-
inducible control of viral replication and viral clearance, 
and increases the anti-viral effect in liver cells that are 
resistant to IFN as well [12].
It is still unclear whether using the gain-of-function of 
STAT1-CC could significantly improve the anti-tumor 
response of IFNs in lung cancer. To address this issue, our 
present study examined the outcome with overexpres-
sion of STAT1 or STAT1-CC genes in lung cancer cells. 
Since fibronectin, β-catenin, S100A4, proliferating cell 
nuclear antigen (PCNA) and c-fos have been reported 
to be involved in the control of cell growth or metasta-
sis in cancers, we also evaluated the effect of STAT1-CC 
on the expression of these proteins in lung cancer cells. 
The results demonstrate that STAT1-CC has strong anti-
tumor effects in lung cancer cells in response to IFNs and 
indicate that combined treatment of IFNs and STAT1-CC 
could be of potential value for further research in  vivo 




Human lung cancer cell lines SPC-A-1 and H1299, and 
human embryonic kidney 293T cells were obtained from 
the Type Culture Collection of the Chinese Academy of 
Sciences, Shanghai, China. SPC-A-1 and H1299 cell lines 
were maintained in RPMI 1640 supplemented with 10 % 
fetal bovine serum (FBS) and 100 U/ml penicillin/strep-
tomycin (Invitrogen, Carlsbad, CA). Human embryonic 
kidney 293T cells were maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10  % FBS and 
100 U/ml penicillin/streptomycin. Cells were cultured in 
a humidified 37 °C incubator with 5 % CO2.
Lentiviral vector construction and transduction
The full-length cDNA of STAT1 or STAT1-CC with Ala-
656 to Cys-656 and Asn-658 to Cys-658 substitutions 
were amplified by PCR from plasmid Mx-STAT1-Flag-
IRES-EGFP-neo and Mx-STAT1-CC-Flag-IRES-EGFP-
neo that were generated as described previously [11]. The 
PCR products were then inserted into a lentiviral vector 
and confirmed by sequencing. The lentivirus particles 
were prepared in 293T cells as described previously [13, 
14]. Lentiviral vectors encoding STAT1-IRES-EGFP and 
STAT1-CC-IRES-EGFP (Fig.  1) were transduced into 
lung cancer SPC-A-1 and H1299 cells to obtain stable 
STAT1- and STAT1-CC-expressing cells. Flow cytometry 
analysis of enhanced green fluorescent protein (EGFP) 
expression was used to detect the relative transduction 
efficiencies of the cell lines.
Western blotting
Cells were lysed on ice with RIPA buffer (Sigma-Aldrich, 
St. Louis, MO, USA) containing protease inhibitor cock-
tail (Sigma-Aldrich). Protein content of the lysates was 
determined using the Bradford Protein Assay kit (Bio-
Rad, Hercules, CA, USA). Equal amounts (40  μg/lane) 
of protein were separated by 12  % SDS PolyAcrylamide 
Gel Electrophoresis (SDS-PAGE) and transferred to poly-
vinylidene fluoride (PVDF) membranes (Millipore, Bed-
ford, MA, USA). The blots were incubated with rabbit 
anti-PCNA antibody (Ab), rabbit anti-phospho-STAT1 
(Tyr701) Ab (Cell Signaling Technology, Beverly, MA, 
USA), rabbit anti-S100A4 Ab (Abcam, Cambridge, UK), 
mouse anti-β-actin Ab (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), mouse anti-fibronectin Ab mouse anti-
β-catenin Ab (Santa Cruz Biotechnology), mouse anti-
STAT1 Ab, and mouse anti-c-fos Ab (Abcam). Primary 
Ab binding was detected with secondary antibody (anti-
mouse or anti-rabbit HRP-conjugated IgG secondary 
antibody) that was detected using enhanced chemilumi-
nescence substrate kit (GE Healthcare, Piscataway, NJ, 
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USA). Quantification was performed with a ChemiDoc 
TM XRS +  scanner and Image Lab Software (Bio Rad, 
CA, USA). The densities of each sample were normalized 
to the β-actin.
Cell viability assay
Cells were seeded into 96-well plates at a density of 
3  ×  103 cells/well. At the following time intervals (24, 
48, 72, 96 and 120  h), cell viability was assayed using 
Cell Counting Kit-8 (CCK-8) assay kit (Dojin Laborato-
ries, Kumamoto, Japan) according to the manufacturer’s 
instructions. To further examine whether STAT1-CC 
could better enhance IFN-induced growth inhibition 
in lung cancer cells, the cells transduced with STAT1, 
STAT1-CC, and EGFP were treated with IFN-γ or IFN-β 
and cell viability was measured using the CCK-8 assay. 
For IFN treatment, 1000 cells were seeded into 96-well 
plates and allowed to attach overnight. Cells were then 
treated with various concentrations of IFN-γ or IFN-β 
(R&D, Minneapolis, MN, USA) at different time inter-
vals. Cell viability was assessed by CCK-8 assay kit.
Cell apoptosis analysis
Cell apoptosis was examined by flow cytometry. Control 
as well as transduced lung cancer cells were plated into 
6-well cell culture plates at a density of 6 × 104 cells/well. 
After treatment with IFN-γ or IFN-β for 4 days, apopto-
sis was assessed by flow cytometry using the Annexin V 
apoptosis detection Kit APC from BD Bioscience (San 
Jose, CA, USA).
Colony formation assay
Both control and transduced lung cancer cells were 
seeded into 10-cm culture dishes at a density of 5000 
cells/dish and were grown in RPMI 1640 containing 10 % 
FBS for 14 days to form colonies. The colonies were then 
stained with Coomassie Blue and imaged accordingly.
Cell migration and invasion assay
The effects of STAT1 and STAT1-CC on migration and 
invasive ability of lung cancer cells in  vitro were exam-
ined using transwell assays. Transwell assays were per-
formed in Costar transwell cell culture chamber inserts 
with an 8 μm pore size, placed in a 24-well cell culture 
plate (Corning Costar Corporation, Cambridge, MA, 
USA) [14]. Biological triplicates were performed for each 
of these assays.
For the cell migration assay, cells (1 ×  105) were sus-
pended in serum-free medium and seeded to the upper 
part of chamber. Complete medium with 10  % FBS 
was added to the lower chamber as a chemoattractant. 
After 24  h, the transwell membrane was fixed with 4  % 
paraformaldehyde, and stained with 0.1  % cresyl violet. 
Migrated cells were counted under a microscope at 400× 
magnification. For the cell invasion assay, cells (1 × 105) 
were suspended in serum-free medium and seeded 
into the upper compartment of the transwell chamber 
coated with 10 μl of diluted Matrigel (BD Biosciences). 
Complete medium with 10  % FBS was added to the 
lower chamber. After 48 h, cells were fixed, stained, and 
counted.
Fig. 1 Lentiviral vector constructs for STAT1 and STAT1-CC. Diagram illustrates the target sequence of the sites for double-cysteine mutations 
in the SH2 domain of STAT1 and subsequent orientation into STAT1 and then into lentiviral vectors expressing EGFP with intervening IRES. The 
abbreviation of STAT1 domains: ND N-terminal domain, CCD coiled coil domain, DBD DNA-binding domain, LD linker domain, SH2D SH2 domain, TD 
transactivation domain
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Statistical analysis
Statistical significance was determined using the Stu-
dent’s t test or analysis of variance (ANOVA). A P value 
of less than 0.05 is considered significant. Data are 
expressed as mean ± SEM.
Results
Expression of STAT1 or STAT1‑CC significantly inhibits lung 
cancer cell growth
In order to overexpress wild type STAT1 and STAT1-
CC mutant in lung cancer cells, we inserted these cDNA 
containing IRES-EGFP sequences into a lentiviral vec-
tor, and at the same time set up EGFP alone as a control 
using the same vector (Fig. 1). The transfection efficien-
cies (EGFP positive cells) of the stable EGFP-, STAT1- or 
STAT1-CC-expressing SPC-A-1 and H1299 cells were 
more than 95  % by flow cytometry analysis. Expres-
sion level of STAT1 or STAT1-CC was verified by west-
ern blot analysis. Interestingly, higher levels of pSTAT1 
were detected in STAT1-CC transduced SPC-A-1 and 
H1299 cells at baseline compared to STAT1 transduced 
cells (Fig.  2a). Cell viability was determined using Cell 
Counting Kit-8 (CCK-8). As shown in Fig. 2b, STAT1 or 
STAT1-CC inhibited SPC-A-1 and H1299 lung cancer 
cell growth under basal culture conditions. Moreover, 
colony formation was significantly decreased in SPC-
A-1 and H1299 cells transduced with STAT1 or STAT1-
CC when compared to those in EGFP-expression cells. 
Colony formation rate for SPC-A-1 cells was 62.9  % in 
the EGFP controls and in cells transduced with STAT1 
or STAT1-CC decreased to 24.7 and 22.6 % respectively. 
In H1299 cells, colony formation rate was reduced from 
82.9 % in EGFP controls to 42.5 % with STAT1 and 40.1 % 
with STAT1CC cells (Fig. 2c, d). These data indicated that 
overexpression of STAT1 or STAT1-CC in lung cancer 
SPC-A-1 and H1299 cells inhibited cell proliferation and 
colony formation.
Expression of STAT1 or STAT1‑CC inhibits invasion 
and migration of lung cancer cells
To examine  the effect of STAT1 or STAT1-CC on the 
migration and invasiveness of lung cancer cells, we per-
formed migration and invasion assays using transwell 
chambers. As shown in Fig.  3a, b, SPC-A-1 cells trans-
duced with STAT1 or STAT1-CC displayed significantly 
decreased migration and invasive abilities when com-
pared to either parent cells or cells transduced with EGFP. 
Reduced migration and invasiveness were also observed 
in H1299 cells transduced with STAT1 or STAT1-CC 
(Fig.  3c, d). STAT1-CC exhibited a stronger inhibitory 
effect on migration and invasiveness compared with wild 
type STAT1 in both lung cancer cell lines.
STAT1‑CC enhances IFNs‑induced growth inhibition of lung 
cancer cells
Under basal culture conditions, both STAT1 and STAT1-
CC have similar effects on inhibition of lung cancer 
cell growth (Fig.  2b), but since in the previous studies, 
STAT1-CC demonstrated hyper-responsive to IFN stim-
ulation [11], we stimulated the cells with various concen-
trations of IFNs. Although STAT1 effectively enhanced 
IFN-γ (1000 U/ml) or IFN-β (1000 U/ml) induced inhibi-
tion of growth at 39.7 and 24.1  %, respectively in SPC-
A-1 cells, transduction with STAT1-CC resulted in a 
greater effect on inhibition of cell growth at 54.9 and 
39.9 %, when cells were treated with the same concentra-
tions of IFN-γ or IFN-β (Fig. 4a, b, e–h). A similar pro-
file was observed in H1299-expressing STAT1 cells at 
inhibition rates of 40.2 and 53.5 % for IFN-γ and IFN-β, 
while inhibition rates of 75.4 and 77.0  % were achieved 
in STAT1-CC cells (Fig. 4c, d). These data indicated that 
STAT1-CC exhibits stronger inhibition of lung cancer 
cell growth with IFN treatment.
STAT1‑CC enhances IFNs‑induced lung cancer cell 
apoptosis
IFNs have potent antiproliferative and apoptosis induc-
ing functions in several types of cancer cells. To exam-
ine whether overexpression of STAT1 or STAT1-CC will 
affect apoptotic events in the transduced lung cancer 
cells, apoptosis was measured using Annexin V apoptosis 
assay. STAT1 or STAT1-CC induced apoptosis in trans-
duced SPC-A-1 cells under normal culture conditions. 
More importantly, STAT1- or STAT1-CC-expressing 
lung cancer SPC-A-1 cells showed increased levels of 
apoptosis compared to parent and EGFP expressing cells 
when treated with either IFN-γ (10,000 U/ml) or IFN-β 
(10,000 U/ml) for 96  h (Fig.  5). Notably, when treated 
with IFN-γ or IFN-β, SPC-A-1 cells transduced with 
STAT1-CC exhibited a significantly increased rate of 
apoptosis compared to cells transduced with wild type 
STAT1.
STAT1‑CC tyrosine phosphorylation was increased 
in transduced lung cancer cells
STAT1 Tyr-701 phosphorylation is an essential step for 
STAT1 activation. As shown in Fig.  6a, overexpression 
of STAT1 or STAT1-CC in SPC-A-1 cells promoted 
STAT1 tyrosine phosphorylation under basal conditions. 
STAT1-CC-expressing cells have a higher pSTAT1 level, 
although the protein level is 2.2- to 2.5-fold lower than 
that in STAT1-expressing cells. To better understand 
the decrease in migration and invasiveness of STAT1-
CC cells, we examined several factors involved in cell 
growth, inhibition, migration and invasion. Expression of 
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Fig. 2 Overexpression of STAT1 or STAT1-CC induces growth inhibition of lung cancer cells. a Western blotting revealed whole cell levels of STAT1 
and pSTAT1 in SPC-A-1 and H1299 cells transduced with lenti-STAT1 or lenti-STAT1-CC. b Overexpression of STAT1 or STAT1-CC resulted in significant 
reductions in the proliferation of SPC-A-1 and H1299 cells (++P < 0.01, lenti-STAT1 vs lenti-EGFP; **P < 0.01, lenti-STAT1-CC vs lenti-EGFP). c, d Repre-
sentative image of foci formation in a monolayer culture. The colony formation rates were significantly decreased in STAT1 and STAT1-CC-expressed 
SPC-A-1 and H1299 cells. Experiments were repeated at least three times. Data are shown as mean ± SEM. **P < 0.01
Fig. 3 Overexpression of STAT1 or STAT1-CC inhibits the migration and invasion of lung cancer cells in vitro. a, c Representative images of migration 
and invasion from indicated groups (at ×400). Overexpression of STAT1 or STAT1-CC inhibited SPC-A-1 (b) and H1299 (d) cell migration and inva-
sion. **P < 0.01
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fibronectin was reduced at similar levels in STAT1- and 
STAT1-CC-expressing cells, while there was a greater 
decrease of β-catenin expression in STAT1-CC cells 
compared to STAT1-expressing cells (Fig.  6a, b). In the 
case of IFN-γ stimulation, the level of pSTAT1 in STAT1-
CC-expressing cells is increased 12.6-fold whereas 
the pSTAT1 level in STAT1-expressing cells is only 
increased 2.2-fold compared to that of EGFP-expressing 
cells (Fig. 6d, f ). Moreover, overexpression of STAT1 or 
STAT1-CC reduced S100A4, PCNA, and c-fos expres-
sions when treated with IFN-γ, greater decreased levels 
of these proteins were observed in STAT1-CC cells com-
pared to STAT1-expressing cells (Fig. 6d). The quantified 
data are shown in Fig. 6b, c and e–i.
Discussion
IFN-γ receptor (ifngr1)-deficient or Stat1-deficient mice 
developed tumors more rapidly compared to wild-type 
mice for both chemically induced and spontaneously 
arising tumors [15]. These data demonstrate that STAT1 
may function as a tumor suppressor. Some spontaneous 
human tumors have been reported to be selectively unre-
sponsive to IFN-γ due to impaired STAT1 activation and 
this suggests that as in mouse models, the IFN-STAT1 
dependent tumor surveillance mechanism also engages 
in humans [16]. Type I and Type II IFNs have been used 
in the treatment of many types of cancers [4]. However, 
IFNs have limited clinical utility in solid tumors, largely 
due to their half-life which makes it difficult to achieve 
sustained therapeutic concentrations [3, 5]. In order to 
overcome  these limitations, many investigators have 
attempted to improve the effects of IFNs through modi-
fication of IFN signaling [11]. Inhibition of endogenous 
inhibitors of STAT1 phosphorylation (e.g. SOCS1) or 
DNA binding (e.g. PIAS1) could be used to modify IFN 
signaling [11, 17, 18]. STAT1-CC with double-cysteine 
substitutions in the Src homology 2 (SH2)-homodimeri-
zation domain markedly increases responsiveness to both 
types I and II IFNs [11]. The mechanism for improving 
IFN efficacy depends on increased capacity for tran-
scriptosome assembly at the promoter of interferon-
stimulated genes (ISGs) that is manifested by prolonged 
STAT1 Tyr-701 phosphorylation, DNA-binding and 
p300/CBP co-activator recruitment [11]. STAT1-CC was 
also shown to be able to overcome IFN-γ resistance and 
induce a hepatitis C virus  antiviral response in IFN-α 
resistant replicon cells [12].
In this study, STAT1 and STAT1-CC genes were suc-
cessfully overexpressed in lung cancer cells using the 
lentivirus-mediated gene transfer system. STAT1 is con-
sidered to play a significant role in regulating cell prolif-
eration and apoptosis [19]. Previous studies have shown 
that STAT1 controls anti-tumorigenic functions by 
upregulating the expressions of caspases 1, 2, 3, 7, and 8 
[20–23] or inducible nitric oxide synthase (iNOS) [19], 
p21 [24] and IRF1/p53 pathway [25], and downregulating 
Fig. 4 Overexpression of STAT1-CC improves IFN-induced growth inhibition in lung cancer cells. a, b SPC-A-1 cell growth inhibition rate was 
determined in each group treated with various doses of IFN-γ or IFN-β for 6 days (*P < 0.05, **P < 0.01). c, d H1299 cell growth was assayed in each 
group treated with IFN-γ 1000 U/ml or IFN-β 1000 U/ml for 2 days. e, f SPC-A-1 cell growth curve was plotted at various time points for each group 
treated with IFN-γ 1000 or 10,000 U/ml. g, h SPC-A-1 cell growth curves were plotted at various time points for each group treated with IFN-β 1000 
or 10,000 U/ml
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expressions of c-myc [26], and the BCL2 family [27]. 
STAT1 also acts as a negative regulator of tumor angio-
genesis partially through the induction of CXCL10 [28]. 
Here, we have examined several factors which have been 
reported to be involved in cell growth, migration, inva-
sion and apoptosis. Fibronectin has been recognized as 
Fig. 5 Overexpressing STAT1-CC enhances IFN-γ or IFN-β induced apoptosis of lung cancer cells. Apoptosis was detected by Annexin V apoptosis 
detection Kit and analysed by flow cytometry. a Flow cytometry results were demonstrated from control, EGFP-, STAT1-, and STAT1-CC-expressing 
SPC-A-1 cells treated with IFN-γ 10,000 U/ml or IFN-β 10,000 U/ml for 96 h. b Quantitative analysis of the population of SPC-A-1 apoptotic cells. c 
Control, EGFP-, STAT1-, and STAT1-CC-expressing H1299 cells were treated with IFN-γ 1000 U/ml or IFN-β 1000 U/ml for 48 h. Quantitative analysis of 
the population of apoptotic cells in Three independent experiments were conducted and data are shown as mean ± SEM. **P < 0.01
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an important protein for cancer invasiveness and metas-
tasis [29, 30], and β-catenin has been shown to play an 
essential role in lung tumorigenesis [31]. The levels of 
both proteins were decreased in STAT1 and STAT1-CC 
transduced lung cancer cells, but there was a greater 
reduction of β-catenin in STAT1-CC cells. STAT1 
undergoes multiple types of post-translational modifi-
cations, e.g. acetylation and ubiquitination in addition 
to phosphorylation. Although we have found that more 
p300/CBP co-activator is recruited to the ISG transcrip-
tional complex in STAT1-CC transduced fibrosarcoma 
cells [11], the acetylation level of STAT1-CC remains 
unclear. Kramer et  al., have shown that acetylated Stat1 
is able to interact with NF-κB p65, resulting in decreased 
p65 DNA binding, nuclear localization, and expression 
of anti-apoptotic NF-κB target genes [32]. Lee et  al., 
reported that NF-κB  activates  fibronectin  gene expres-
sion in rat hepatocytes [33]. It will be interesting to look 
at the acetylation level of STAT1-CC in lung cancer cells. 
β-catenin has been reported to physically interact with 
NF-κB to form a complex, resulting in reduced NF-κB 
DNA binding and target gene expression. Moreover, a 
strong inverse correlation was found between the expres-
sion levels of β-catenin and Fas in colon and breast tumor 
tissues [34]. We will therefore examine whether Fas level 
was increased in STAT1-CC cells. S100A4 is associ-
ated with increased cell growth and metastatic capacity 
of lung cancer cells, and, PCNA plays an important role 
in DNA replication and repair. It has been revealed that 
PCNA is a potential anticancer target [35]. Both S100A 
and PCNA expression are suppressed by IFN-γ [36, 37]. 
c-fos proto-oncogene is described as an immediate early 
response gene, in which the high expression of c-fos can 
induce the formation of tumors [38]. Interferon-α-2b 
downregulates the expression of c-fos, H-ras, c-raf-2, 
c-kit, c-myc, and c-myb in a hairy cell leukemic line [39]. 
Expression of S100A4, PCNA and c-fos were reduced 
in STAT1- and STAT1-CC-expressing lung cancer cells, 
while PCNA and c-fos were decreased to a greater extent 
in STAT1-CC cells. STAT1 phosphorylation is higher in 
Fig. 6 STAT1-CC increases STAT1 phosphorylation in lung cancer cells. a Western blot for pSTAT1, fibronectin and β-catenin in STAT1- or STAT1-
CC-expressing SPC-A-1 cells. d Western blot for pSTAT1, S100A4, PCNA and c-fos in STAT1- or STAT1-CC-expressing SPC-A-1 cells treated with IFN-γ 
(1000 U/ml) for 72 h. β-actin was used as a loading control. b, c, e–i Western blot levels of indicated proteins were quantified with the ChemiDoc ™ 
XRS+ scanner and Image Lab Software imaging system in the SPC-A-1 cells. The densities of each sample were normalized to the β-actin
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STAT1-CC cells both at baseline and with IFN-γ treat-
ment. This indicates that the IFN-STAT1 signaling path-
way is more active in this cell line, and might represent 
a potential molecular mechanism in which STAT1-CC 
could enhance the antitumor response of IFNs through 
upregulation of gene expression involved in inhibition 
of cell growth and metastasis in lung cancer cells. The 
mechanism for regulation of these genes needs further 
study.
The delivery of therapeutic genes into lung cancer cells 
is still a challenging approach in gene therapy. Recently, 
Powell et  al., reviewed methods by which viral vec-
tors can be engineered to enhance target specificity and 
increase transgene expression [40]. On the other hand, 
the development of small molecules that are able to 
enhance IFN signaling would validate a roadmap for next 
generation drugs for treatment of interferon-sensitive 
tumors [41, 42].
Conclusions
In conclusion, overexpression of STAT1 or STAT1-CC 
inhibits human lung cancer cell proliferation, migration 
and invasion, and enhances the antitumor response of 
IFNs in vitro. STAT1-CC has stronger IFN induced anti-
tumor activity than STAT1 through enhanced STAT1 
phosphorylation in lung cancer cells. Together, these data 
suggest that combined treatment of IFNs and STAT1-
CC may represent a useful therapeutic strategy for the 
clinical management of human lung cancer, though this 
approach must be evaluated for the safety and efficacy by 
clinical trials before any clinical applications.
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